Affiliation:
1. Vascular Mechanics Laboratory, Experimental Therapeutic and Clinic Institute, Health Sciences University Centre,
University of Guadalajara, Guadalajara, Mexico
2. Department of Physiology, Pharmacology, Health Sciences University
Centre, University of Guadalajara, Guadalajara, Mexico
Abstract
Objective:
Obesity, a major health issue worldwide, is associated with increased cardiovascular
risk, endothelial dysfunction, and arterial stiffness. Tadalafil has been demonstrated to improve
vascular parameters.
Aim:
To evaluate the effect of a single 20 mg dose of tadalafil on flow-mediated dilation and hemodynamic
and arterial stiffness markers.
Methods:
A randomized, double-blind, placebo-controlled study was conducted on 80 participants (41
assigned to placebo and 39 to tadalafil) with grade 1 obesity, to evaluate the acute effect of a single dose
of 20 mg of tadalafil on flow-mediated dilation and hemodynamic and arterial stiffness markers.
Results:
Tadalafil did not modify flow-mediated dilation. However, it significantly lowered systolic
blood pressure (SBP) (130.6±17.1 vs. 125.0±12.7 mmHg, p=0.011), diastolic blood pressure (82.7±18.2
vs. 76.5±11.8 mmHg, p≤0.001), central systolic blood pressure (116.33±19.16 vs. 109.90±15.05 mmHg,
p=0.001), the augmentation index (69.1±17.1 vs. 65.7±14.4, p=0.012), and brachial-ankle pulse wave
velocity (1229.7±218.4 vs. 1164.0±181.7, p=0.001).
Conclusion:
A single dose of tadalafil did not modify flow-mediated dilation in patients with grade
1 obesity but improved blood pressure and brachial-ankle pulse wave velocity.
Clinical Trial Registration Number:
The clinical trial registration number is (NCT03905018).
Publisher
Bentham Science Publishers Ltd.
Subject
Cardiology and Cardiovascular Medicine,Pharmacology